Long-term memory B-cell responses in recipients of candidate human immunodeficiency virus type 1 vaccines (Q40546496)

21 September 2017

Long-term memory B-cell responses in recipients of candidate human immunodeficiency virus type 1 vaccines (English)

1 reference

21 September 2017

1 reference

8

David C Montefiori

1 reference

21 September 2017

2

Sharon Frey

1 reference

21 September 2017

1

Thomas G Evans

1 reference

21 September 2017

Heidi Israel

3

1 reference

21 September 2017

Joseph Chiu

4

1 reference

21 September 2017

Raphaelle El-Habib

5

1 reference

21 September 2017

Peter Gilbert

6

1 reference

21 September 2017

Alicia Gaitan

7

1 reference

21 September 2017

HIV Vaccine Trials Network (HVTN 803)

9

1 reference

21 September 2017

language of work or name

English

0 references

publication date

1 June 2004

1 reference

21 September 2017

1 reference

21 September 2017

22

1 reference

21 September 2017

20

1 reference

21 September 2017

2626-2630

1 reference

Prospects for vaccine protection against HIV-1 infection and AIDS.

21 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.011

Neutralizing antibodies administered before, but not after, virulent SHIV prevent infection in macaques.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.011

Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.011

Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.011

Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.011

Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.011

Viremia control despite escape from a rapid and potent autologous neutralizing antibody response after therapy cessation in an HIV-1-infected individual

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.011

Passive immune globulin therapy in the SIV/macaque model: early intervention can alter disease profile

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.011

The HIV-1 Envelope Glycoproteins: Fusogens, Antigens, and Immunogens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.011

Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Ev

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.011

Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.011

Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.011

A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.011

Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group Protocol 022A.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.011

Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.011

Safety profile of phase I and II preventive HIV type 1 envelope vaccination: experience of the NIAID AIDS Vaccine Evaluation Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.011

Identification of human immunodeficiency virus subtypes with distinct patterns of sensitivity to serum neutralization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.011

Genetic analysis of HIV-1 isolates from Brazil reveals presence of two distinct genetic subtypes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.011

Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: recombinant glycoprotein (rgp) 120. A randomized, double-blind trial. NIAID AIDS Vaccine Evaluation Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.011

A Phase II Study of Two HIV Type 1 Envelope Vaccines, Comparing Their Immunogenicity in Populations at Risk for Acquiring HIV Type 1 Infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.011

Advances in vaccine adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.011

Toward an HIV type 1 vaccine that generates potent, broadly cross-reactive neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.011

Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.011

inferred from DOI database lookup

7 January 2021

based on heuristic

Evaluation of antiviral drugs and neutralizing antibodies to human immunodeficiency virus by a rapid and sensitive microtiter infection assay.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.011

inferred from DOI database lookup

7 January 2021

based on heuristic

Characterization of primary isolate-like variants of simian-human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.011

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2003.12.011

1 reference

21 September 2017

1 reference